Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
Mo | CELZ stock touches 52-week low at $2.49 amid market challenges | 1 | Investing.com | ||
Mo | CELZ-Aktie erreicht 52-Wochen-Tief bei 2,49 US-Dollar | 1 | Investing.com Deutsch | ||
13.11. | Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment | 52 | GlobeNewswire (Europe) | PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology leader in regenerative medicine, is pleased to announce the successful completion... ► Artikel lesen | |
08.11. | Creative Medical Technology files to sell 0.83M shares of common stocks by selling shareholders | 1 | Seeking Alpha | ||
08.11. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
08.11. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
08.11. | CELZ stock touches 52-week low at $2.65 amid market challenges | 2 | Investing.com | ||
23.10. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
04.10. | Creative Medical Technology files for $50M mixed securities shelf | 3 | Seeking Alpha | ||
09.08. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
25.07. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
24.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program | 1 | GlobeNewswire (USA) | ||
10.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Provides Corporate Update | 89 | GlobeNewswire (Europe) | PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative... ► Artikel lesen | |
24.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin | 84 | GlobeNewswire (Europe) | PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company... ► Artikel lesen | |
20.12.23 | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem For Addressing Chronic Lower Back Pain | 650 | ACCESSWIRE | PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,500 | -15,59 % | ASML, Defama, Evotec, Mercedes-Benz, Smartbroker, Süss MicroTec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
BIONTECH | 108,90 | +0,28 % | Übernahmefantasie und Momentum: BioNTech, Rheinmetall, Vidac Pharma Aktie | BioNTech will seine Pipeline für den Kampf gegen Krebs stärken und die chinesische Biotechfirma Biotheus übernehmen. Dafür legen die Mainzer für das auf die Entwicklung von Therapien für Krebs- und... ► Artikel lesen | |
DYNE THERAPEUTICS | 29,690 | -0,27 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
MODERNA | 39,575 | +0,18 % | Opening Bell: Bitcoin, Tesla, Moderna, Netflix, Palantir, Nvidia | Vor dem Wochenende ging es für den Dow Jones um 0,7 Prozent abwärts. Auch auf Wochensicht fuhr er Verluste ein, hier gab er 1,3 Prozent ab. Der Nasdaq 100 verlor sogar 2,4 Prozent in der vergangenen... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
RELAY THERAPEUTICS | 4,750 | +2,37 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |